missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Phospho-FOXO4 (Ser197) Polyclonal Antibody

Description
This antibody detects endogenous protein at a molecular weight of 55 and 70 kDa. Purity is >95% by SDS-PAGE.
FOXO4 (Forkhead box O4) is encoded by the FOXO4 gene located on the X chromosome. It is also known as AFX1 or MLLT7 (Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Translocated To, 7) and is a member of the O class of forkhead/ winged helix family of transcription factors along with FOXO1, FOXO3 and FOXO6. FOXO4 is abundantly expressed in skeletal muscle and adipose tissue. FOXO4 binds to the Insulin Responsive Element (IRE) and activates downstream targets of Insulin/IGF1 signaling such as IGFBP1. However, the activation of another downstream target of the Insulin/IGF1 pathway, Akt, leads to phosphorylation of FOXO4 on specific Ser/Thr residues. This phosphorylation mediates binding of FOXO4 to 14-3-3 and eventual exit of FOXO4 from the nucleus.
Specifications
Specifications
| Antigen | Phospho-FOXO4 (Ser197) |
| Applications | Immunohistochemistry (Paraffin), Western Blot |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.02% sodium azide; pH 7.2 |
| Gene | FOXO4 |
| Gene Accession No. | P98177, Q9WVH3 |
| Gene Alias | AFX; Afx1; Afxh; AFXzeta; Fkhr3; Fork head domain transcription factor AFX1; forkhead box O4; forkhead box protein O4; forkhead protein; FOXO4; FOXO4b; MGC120490; MLLT7; myeloid/lymphoid or mixed lineage-leukemia translocation to 7 homolog; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 7; OTTHUMP00000023497; RGD1561201 |
| Gene Symbols | FOXO4 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?